Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b pivotal study of izokibep in non-infectious intermediate, posterior, or pan-uveitis
2021-006498-49Phase 2Active
- Sponsor
- Acelyrin
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of izokibep in uveitis and Hyalitis (3 arms), sponsored by Acelyrin. Primary endpoint: Time to treatment failure. Started Apr 2022; status: active.
02
Drugs
izokibep
03
Conditions
uveitisHyalitis
Beyond the preview
Go deeper on 2021-006498-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006498-49.